GILZ formulations for wound healing

Patent metadata

Field	Value
Publication number	US-11524091-B2
Application number	US-201916541252-A
Country	US
Kind code	B2
Filing date	Aug 15, 2019
Priority date	Aug 21, 2018
Publication date	Dec 13, 2022
Grant date	Dec 13, 2022

Abstract

Glucocorticoid-induced leucine zipper protein (GILZ) peptide compositions and their methods of use in wound healing are disclosed herein. An exemplary GILZ peptide composition includes a GILZ fusion protein. The GILZ peptide compositions can be administered topically to wounds, for example in the form of a cream, ointment, or lotion. The GILZ peptide compositions can be used to treat acute wounds, induce wound healing in chronic wounds, and reduce scar formation.

First claim

We claim:

1. A method for promoting skin wound or lesion healing comprising, administering to the wound a composition comprising a GILZ peptide having 95, 98, 99, or 100% sequence identity to SEQ ID NO:1 fused to a cell penetrating peptide according to SEQ ID NO:4 in an amount effective to reduce inflammation and enhance wound healing.

2. The method of claim 1 , wherein the skin wound or lesion is acute.

3. The method of claim 2 , wherein the acute skin wound or lesion is selected from the group consisting of surgical wound, abrasions, incisions, lacerations, first degree burns, second degree burns, or third degree burns.

4. The method of claim 1 , wherein the skin wound or lesion is chronic.

5. The method of claim 4 , wherein the chronic skin wound or lesion is selected from the group consisting of venous leg ulcer, arterial leg ulcer, or decubitus ulcer.

6. The method of claim 1 , wherein the skin wound or lesion is fibrotic.

7. A method of reducing scar formation in a skin wound or lesion comprising, administering to the wound a composition comprising a GILZ peptide having 95, 98, 99, or 100% sequence identity to SEQ ID NO:1 fused to a cell penetrating peptide according to SEQ ID NO:4 in an amount effective to enhance wound healing and reduce scar formation, wherein the composition is administered to the wound daily.

8. The method of claim 7 , wherein the composition is formulated for topical administration.

9. The method of claim 8 , wherein the topical composition is a cream, ointment, or spray.

10. The method of claim 7 , wherein the composition is comprised in a wound dressing.

11. A method for reducing an inflammatory response at a site of a skin wound or lesion in a subject in need thereof, comprising:
locally administering a composition comprising a GILZ peptide having 99 or 100% sequence identity to SEQ ID NO:1 fused to a cell penetrating peptide according to SEQ ID NO:4 to a site of inflammation in an amount effective to reduce immune cells infiltrating into the site, wherein the immune cells comprise neutrophils, and wherein the site of inflammation is located at the site of the skin wound or lesion.

Assignees

• Univ Res Inst Inc Augusta

Inventors

• Mozaffari Mahmood
• Baban Babak
• Abdelsayed Rafik

Classifications

• C07K14/4702

  Regulators; Modulating activity · CPC title

• A61K38/1709 Primary

  from mammals · CPC title

• A61L26/0066

  Medicaments; Biocides · CPC title

• A61L15/20

  containing organic materials · CPC title

• A61L15/32

  Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)} · CPC title